There are independent studies showing that drug developed for treatment of RA can also be used to treat T2D.Recent studies have demonstrated that treatment with TNF antagonists alters the lipid profile and improves insulin sensitivity inpatients with RA, but not so effective in early stage. Another example, the thiazolidinediones is used in the treatment of T2D, as wells as show the inhibition of T-cell activation and Skepinone-L inflammatory disease. These classes of drugs are of growing importance as atherapeutical approach in inflammatory and autoimmune diseases such as RA by regulating IL-17A, IL-22, and IFN-�� levels, but with a few significant cardiovascular side effects. Thus, because of the limited targets and side PF-573228 effects of those drugs, as well as the complexity of both the two disorders, the discovery of satisfied and novel treatment or drugs targets effective on both RA and T2Dwas blocked no doubt. So that, the commonality of RA and T2D at molecular level mechanism screening in order to provide more information for developing conjunct treatment targets on both RA and T2Dmaybe one strategy was called. Recently, several high-throughput techniques are used to study the expression of mRNAs, such as the next-generation sequencing platforms, which have the advantages of greater sensitivity and more precise quantification, providing a more complete result of the transcriptome in studies of gene expression compared with a micro array. Measurements of mRNA expression by RNA sequencing have proven to be valuable for identification of the molecular changes that occur in cells, provide clues for molecular networks in diseases process. Currently, one of NGS protocols:30- tag digital gene expression developed by Illumina have been widely used for transcriptome studies. There are reports focusing on the molecular mechanisms of pathophysiologic changes during RA or T2D independently by transcriptome or gene expression profiles technology, but few reports concerning the associations between RA and T2D at the transcriptome level, neither in-depth study on the mechanisms and the molecular networks on the commonly shared pathways between RA and T2D.